Pain Management

This year's meeting highlighted the opioid epidemic and ways pharmacists can improve patient care.

This week, take a look at studies and news on supplements, depression, opioids, and more. Small doses is the news you need in a way that works for you.

How PDMPs are helping both patients and pharmacists.

A look at PDMPs in PA-what they are doing and how they are helping patients.

Rite Aid and Albertsons expand naloxone Access, hoping to curb the opioid epidemic.

A look at four important drug studies and stories that you need to know about.

A new CDC study shows that drug overdose deaths have been on the rise and are likely to keep rising.

A pharmacy in Pennsylvania allowed a man to pick up his mother's prescription for fentanyl after being told not to allow it, with tragic results.

Epinephrine saves lives. So does naloxone. Why are they regarded differently?

Pharmacists are the most accessible healthcare resource. Once trained in naloxone use, we can train our patients in all aspects of opioid use. This will make a difference.

"Naloxone should be the fire extinguisher in the home of everyone who is at risk."

The movement to get naloxone into the hands of first responders, drug users, and their family members has found increasing support in state legislatures.

It's a modest proposal with potential for significant consequences. And all it will cost is a little more time.

141 generic and 87 branded immediate-release opioid pain medications will be affected.

Continuous monitoring is what's needed. Fortunately, there's a platform for that.

In this month's trip down Memory Lane, Drug Topics looks back on an article from 2001 that examined the roots of a problem in full flower today.

Letters, e-mails, comments, and posts from Drug Topics readers

Don't let the prescriber's hostility stop you from doing the right thing. As the pharmacist, you're the Rx expert.

An overly aggressive government is making a tough job tougher, but the pharmacist's first ethical concern must be for the patient.

Asking whether hydrocodone should be rescheduled is only the beginning.

Will FDA classify hydrocodone as Schedule III, Schedule II, or somewhere in between?

A new bimonthly column from Ken Baker looks at ethical decision-making in pharmacy.